Antineoplastic Agents

Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro. Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.

Capecitabine, an antimetabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in vivo, was developed by Roche under the trade name hiloda and is able to inhibit cell division and interfere with RNA and protein synthesis. For further treatment of paclitaxel and advanced primary or metastatic breast cancer including patients refractory to chemotherapeutic regimens with anthracyclines. It is mainly used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancer.

This product is an anti-tumor drug.

Antimetabolic drugs. The main indication is acute myeloid leukemia which is ineffective to conventional treatment. It is also used for breast cancer, melanoma, intestinal cancer and so on. The main manifestations of toxicity were leucopenia, thrombocytopenia and anemia. Nausea and vomiting are common adverse reactions. Symptoms can be improved by continuous infusion for a long time, or antiemetic agents can be used 24 to 48 hours before treatment. Other toxic effects were diarrhea, neuromuscular disorders, fever, hypotension and rash. The preparation is freshly prepared 3-4h before use.

Bendamostine hydrochloride was first developed by ozegowski and his colleagues in the microbial experimental Association in Jena, Germany in the early 1860s. The initial purpose was to connect an alkylated nitrogen mustard (a non effective alkylating agent) with a purine and an amino acid. Compared with nitrogen mustard phenylbutyrate, the main advantage of the newly synthesized compound is its water solubility. It was widely used, but until the end of the cold war, the drug has been carried out in Europe for many single drugs or other drugs for the treatment of various hematological malignancies or non Hodgkin's lymphoma, multiple myeloma, CLL and breast cancer. The clinical effect is very significant, significantly reducing the rate of recurrence and mortality, and has little side effects. Good security. So far, bendamostine hydrochloride single drug or combined treatment has been designated as the first-line or second-line treatment option for a variety of hematological malignancies by European and American clinical guidelines.